Takeda’s GI Drug Discovery Unit will work closely with experts from QMUL’s School of Medicine and Dentistry’s neurogastroenterology and immunology groups on several areas of research, including identifying novel therapeutic targets and researching the effect of compounds with novel mechanisms of action. The focus of the research alliance will be GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders.
More articles on GI/endoscopy:
Gotham Medical Associates selects PriorityOne for GI practice IT implementation
Boston Scientific announces 2 product updates
CRE infections at UCLA Medical Center transmitted during ERCP
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
